本报道最初发表于Endpoints News。请点击这里查看原文
Just as Maziar Mike Doustdar took the helm at Novo Nordisk in the summer of 2025, the company said it would reorganize its R&D activities, merging the teams that focused on early research and work in the clinic.
就在马兹亚尔•迈克•道斯达(Maziar Mike Doustdar)于2025年夏天出任诺和诺德(Novo Nordisk)掌门人之际,该公司表示将重组其研发活动,把负责早期研究和临床开发的团队合并在一起。
您已阅读3%(347字),剩余97%(9888字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。